Search - tctmd.com

Displaying 381 - 400 of 4045

Sort: Relevancy | Date

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

Presentation TCT 2024

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presenter: Ryo Hikida

October 29, 2024

Presentation TCT 2024

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Presenter: Raymond Townsend

October 29, 2024

Presentation TCT 2024

Debate Con: RDN Will Ultimately Be a Niche Therapy

Presenter: Andrew Sharp

October 29, 2024

Presentation TCT 2024

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Presenter: Eric Secemsky

October 29, 2024

Presentation TCT 2024

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Presenter: Michael Weber

October 29, 2024

Presentation TCT 2024

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

Presenter: Michael Bloch

October 29, 2024

Presentation TCT 2024

What Evaluation is Required for Patient Selection for RDN?

Presenter: Naomi Fisher

October 29, 2024

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

L.A. McKeown

October 28, 2024

Presentation TCT 2024

The New CKM Scientific Statement: Expanding the Cardiometabolic Focus and Including the Kidney

Presenter: Chiadi Ndumele

October 28, 2024

Presentation TCT 2024

TCT 485: Device-Related Adverse Events and Modes of Failure Related to Renal Denervation Systems: Insights From Analysis of the FDA MAUDE Database

Presenter: Manasa Jasti

October 28, 2024

Presentation TCT 2024

TCT 486: Ultrasound Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated Trial

Presenter: Roland Schmieder

October 28, 2024

Presentation TCT 2024

TCT 484: Twelve Week Safety and Efficacy of a Novel Extravascular Bi-lateral Renal Denervation Device in a Porcine Model at Nominal Dose

Presenter: Abraham Tzafriri

October 28, 2024

Presentation TCT 2024

TCT 482: Anatomical Predictors for Blood Pressure Outcome After Endovascular Ultrasound Renal Denervation

Presenter: Karl Fengler

October 28, 2024

Presentation TCT 2024

TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus

Presenter: Daria Feshchenko

October 28, 2024

Presentation TCT 2024

TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

Presenter: Felix Mahfoud

October 28, 2024

News Conference News TCT 2024

Radiation Survey Reveals Variable Practices as Operators Look to Themselves for Fixes

L.A. McKeown

October 27, 2024

Advertisement

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Debate Con: RDN Will Ultimately Be a Niche Therapy

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

What Evaluation is Required for Patient Selection for RDN?

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

The New CKM Scientific Statement: Expanding the Cardiometabolic Focus and Including the Kidney

TCT 485: Device-Related Adverse Events and Modes of Failure Related to Renal Denervation Systems: Insights From Analysis of the FDA MAUDE Database

TCT 486: Ultrasound Based Renal Denervation Reduces Blood Pressure in Patients With Chronic Kidney Disease: Results of a Multicenter Prospective Randomized Sham-Controlled Blinded Investigator Initiated Trial

TCT 484: Twelve Week Safety and Efficacy of a Novel Extravascular Bi-lateral Renal Denervation Device in a Porcine Model at Nominal Dose

TCT 482: Anatomical Predictors for Blood Pressure Outcome After Endovascular Ultrasound Renal Denervation

TCT 483: One Year Follow-Up Effect of Renal Sympathetic Denervation After Percutaneous Coronary Intervention in Patients With Resistant Hypertension and Type 2 Diabetes Mellitus

TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

Radiation Survey Reveals Variable Practices as Operators Look to Themselves for Fixes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content